Helping patients reclaim a life of possibility
Sandoz, a manufacturer of generic medicines, announced the launch of generic lenalidomide in 19 European countries. You can see the full press statement here. Alternatively known under the branded name “Revlimid”, lenalidomide is a drug licensed and commonly used in the treatment of myeloma – in newly diagnosed, maintenance and relapsed settings. Lenalidomide…
Today Myeloma Patients Europe (MPE) published our 2021: Year in Review, a snapshot of the major accomplishments from the past year. In 2021, MPE launched two projects that will provide distinct and indispensable resources for the patient community: the launch of the redesigned Myeloma Access Atlas, helping the patient community to advocate more effectively…
Myeloma Patients Europe (MPE) has today relaunched the Myeloma Access Atlas, an online platform designed to provide myeloma and AL amyloidosis patient advocates with the information and tools needed to work effectively on access issues. Explore the Platform here. The Atlas provides country-specific and comparative information on European healthcare systems, including data on system…
Myeloma Patients Europe (MPE) is seeking research grant applications, for funding of up to 100k €, on a project exploring shared-decision making in myeloma. If you are interested, please read the information below and complete the following application form. Deadline for submission is 3 pm CET on Friday 5th of November 2021